• Pharmacovigilance
• Communicable Diseases
• DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS
• Education, Pharmacy, Continuing
• CRITICAL CARE

We have reviewed with great interest the case report published by Belančić et al entitled ‘Afatinib-induced toxic epidermal necrolysis: A case report with a literature review’.1 This study presents an interesting and significant case in the fields of oncology and pharmacovigilance, focusing on a rare but severe adverse event in an oncological patient treated with afatinib. The research focuses on the detailed documentation of toxic epidermal necrolysis (TEN)/Stevens–Johnson syndrome (SJS), a potentially life-threatening condition that manifested 8 days after the initiation of drug therapy. The authors conducted a systematic literature review, identifying only five previous cases. This highlights the rarity of the event and the importance of accurately documenting it to expand knowledge of the drug’s side effects. The study provides valuable insights into the immunological mechanisms underlying TEN/SJS, …